APTOF · As filed with the SEC
Aptose Biosciences income statement, by fiscal year
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Loss and Comprehensive Loss · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Operating expenses: | ||||
| Research and development, related party | — | 0 | 3,492,000 | — |
| Research and development | 11,341,000 | 15,103,000 | 33,273,000 | 28,088,000 |
| General and administrative | 13,382,000 | 11,154,000 | 15,591,000 | 14,514,000 |
| Total operating expenses | 24,723,000 | 26,257,000 | 52,356,000 | 42,602,000 |
| Other income (expenses): | ||||
| Interest income | 105,000 | 357,000 | 1,151,000 | 788,000 |
| Interest expense, related party | — | (207,000) | — | — |
| Interest expense, related party | (843,000) | — | — | — |
| Change in fair value of warrants | 0 | 686,000 | — | — |
| Foreign exchange loss | (7,000) | (9,000) | (2,000) | (9,000) |
| Total other (expenses) income | (745,000) | 827,000 | 1,149,000 | 779,000 |
| Net loss and comprehensive loss | (25,468,000) | (25,430,000) | (51,207,000) | (41,823,000) |
| Unrealized gain on available-for-sale securities | — | 0 | 2,000 | (2,000) |
| Total comprehensive loss | — | (25,430,000) | (51,205,000) | (41,825,000) |
| Net loss per common share, basic | (10.41) | (36.38) | (7.58) | (0.45) |
| Net loss per common share, diluted | (10.41) | (36.38) | (7.58) | (0.45) |
| Weighted-average number of common shares outstanding, basic | 2,447,353 | 698,980 | 6,755,000 | 92,267 |
| Weighted-average number of common shares outstanding, diluted | 2,447,353 | 698,980 | 6,755,000 | 92,267 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.